Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) (603567) disclosed the restricted stock incentive plan on the evening of February 6, which is also the first equity incentive plan launched by Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) since its IPO in 2015. This equity incentive plan mainly focuses on the front-line R & D and business backbone personnel of the company. The grant price is 7.37 yuan / share, and the closing price of the company’s shares on January 28 is 13.36 yuan / share. This move aims to fully activate the enthusiasm of the management team and core backbone, realize the company’s strategy, and maintain and enhance the company’s market competitiveness.
The total number of incentive objects is 51, including 5 senior managers and 46 core R & D and business backbone personnel. The stock source of the incentive plan is Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) to issue 1.5 million shares to the incentive objects, accounting for 0.159% of the total share capital of the company on the announcement date.
The restricted shares granted by the incentive plan are restricted for 12 months, 24 months and 36 months respectively from the date of completion of the registration of restricted shares, and the corresponding proportion of restrictions that can be lifted is 30%, 30% and 40% respectively. The assessment year for the lifting of sales restrictions is three fiscal years from 2022 to 2024.
It is reported that the assessment indicators at the company level require that the combination indicators of three dimensions must be met at the same time every year, that is, the proportion of the total annual R & D expenditure in the operating revenue of the current year shall not be less than 5%; Based on the audited financial data of 2021, the annual compound growth rate of sales revenue of oral preparation products shall not be less than 40%; Based on the annual audited financial data of the previous year, the increase of annual accounts receivable turnover rate in the three assessment periods shall not be less than 3%, 4% and 5% respectively. In addition, the individual level assessment of incentive objects shall be implemented in accordance with the relevant provisions of the company’s current salary and assessment. On the premise of the achievement of the company’s performance appraisal objectives, the company will determine the proportion of lifting the sales restriction according to the annual performance appraisal results of the incentive objects.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) adhering to the R & D concept of “comprehensive innovation” of traditional Chinese medicine, chemical medicine and biological medicine, focusing on the fields of advantageous diseases such as cardio cerebrovascular, respiratory system and tumor, adhering to the dual development strategy of injection and oral agent, constantly optimizing the product structure, consolidating the main business, and further stabilizing the leading position in the traditional Chinese medicine industry.
It is worth mentioning that after reasonable prediction and taking into account the incentive role, this equity incentive plan selects the index reflecting the profitability of the enterprise “sales revenue of oral preparation products”, the index reflecting the operation ability of the enterprise “turnover rate of accounts receivable” and the index reflecting the long-term development potential “the proportion of total R & D expenditure in operating revenue” as the performance evaluation index.
Sales revenue is one of the important indicators reflecting the sustainable operation ability of enterprises. The incentive plan points out that the target of “sales revenue of oral preparation products” is selected in consideration of the fact that the company will accelerate the development and sales of oral preparations in the future to improve the overall revenue level. The specific value has been reasonably predicted and comprehensively considered the possibility and incentive effect. Therefore, the company has set an annual compound growth rate of no less than 40% of the sales revenue of oral preparations in each year from 2022 to 2024 based on 2021 in the three lifting periods.
The turnover rate of accounts receivable is one of the important indicators reflecting the operation quality of enterprises. The incentive plan points out that this index is selected in consideration of the company’s fine management of accounts receivable and improvement of payment collection ability in order to control the benign development of cash flow in the future business expansion. The specific value has been reasonably predicted and comprehensively considered the possibility and incentive effect. Therefore, the company has set the above accounting year as the basis in the three lifting periods, and the growth rate of accounts receivable turnover rate in each year from 2022 to 2024 is not less than 3%, 4% and 5%.
The proportion of total R & D expenditure to operating income is one of the important indicators to reflect the long-term development potential of enterprises. The incentive plan points out that this index is selected considering that the company has completed the R & D system of “one heart, three hospitals”. In the future, it will be based on the traditional advantages of traditional Chinese medicine R & D, drive the R & D of innovative drugs, and maintain the benign development trend of new variety application and approved listing every year. Therefore, the proportion of R & D expenditure in the total sales quota of the company is not lower than 5% in the three periods.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) indicates that the assessment system of the company’s incentive plan is comprehensive, comprehensive and operable; The setting of assessment indicators has good scientificity and rationality, and multi-dimensional focus and promote the high-quality development of the company.
